查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612571

生物标记市场：按产品/服务、类型、疾病和应用分类 - 全球预测 2025-2030

Biomarkers Market by Product & Service (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生物标记市场价值为525亿美元，预计到2024年将达到596.9亿美元，复合年增长率为14.19%，到2030年将达到1329.8亿美元。

生物标记（生物标记）是一种在体液和组织中发现的特征性生物特征，显示正常或异常状况、疾病阶段或治疗效果。它对于诊断、临床试验、个人化医疗和药物开发至关重要，并加深我们对疾病机制和治疗效果的理解。生物标记用于肿瘤学、心臟病学、神经病学和感染疾病等领域。慢性病的增加、生物标记研究的技术进步以及精准医疗需求的快速增长推动了市场成长。基因生物标誌物的创新，特别是透过人工智慧和资料分析的进步，为客製化个人化治疗计画和预测疾病进展提供了重要机会。液态切片和多组体学物标记等新领域正在引起人们的关注，因为它们有可能更快、更准确地检测疾病。然而，挑战包括检验成本高、监管复杂性以及有关基因资料隐私的道德问题。此外，疾病异质性和生物标记检验缺乏标准化正在阻碍市场扩张成长。透过探索非侵入性生物标记和人工智慧增强的分析工具，可以实现持续创新。整合数位健康资料和现实世界的证据可以带来更具预测性的诊断。透过投资跨产业合作，公司可以透过确保采用稳健的多学科方法来发现生物标誌物，从而获得竞争优势。鼓励开放资料共用和标准化通讯协定可以改善一些现有障碍。随着生物标记物市场的发展，灵活应对监管变化和技术进步将是持续成长的关键。透过强调与医疗保健提供者和患者的伙伴关係，生物标记的应用将变得更加创新，从而显着改善健康结果和个人化医疗保健解决方案的市场渗透率。

主要市场统计
基准年[2023] 525亿美元
预测年份 [2024] 596.9亿美元
预测年份 [2030] 1329.8亿美元
复合年增长率（%） 14.19%

市场动态：揭示快速发展的生物标誌物市场的关键市场洞察

供需的动态交互作用正在改变生物标记市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 越来越多地使用生物标记来早期检测和诊断慢性病
    • 政府和监管机构对生物标记研究的支持
    • 扩大生物标记在个人化医疗中的使用
  • 市场限制因素
    • 与生物标誌物开发相关的高成本和技术问题
  • 市场机会
    • 将生物标记物与人工智慧和机器学习结合
    • 人们对开发先进的非侵入性生物标记越来越感兴趣
  • 市场挑战
    • 关于使用生物标誌物的伦理和法律问题

波特的五力：驾驭生物标记市场的策略工具

波特的五力架构是了解生物标记市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物标记市场的外部影响

外部宏观环境因素在塑造生物标记市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解生物标记市场的竞争状况

生物标记物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生物标记市场供应商的绩效评估

FPNV定位矩阵是评估生物标记市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製生物标誌物市场的成功之路

生物标誌物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 更多使用生物标记来早期检测和诊断慢性病
      • 政府和监管机构对生物标记研究的支持
      • 扩大生物标记在个人化医疗的应用
    • 抑制因素
      • 与生物标誌物开发相关的高成本和技术问题
    • 机会
      • 将生物标记物与人工智慧和机器学习结合
      • 人们对开发先进的非侵入性生物标记越来越感兴趣
    • 任务
      • 关于使用生物标誌物的伦理和法律问题
  • 市场区隔分析
    • 产品和服务：越来越多地采用先进且易于使用的生物标记软体来处理复杂的生物资料。
    • 应用：生物标记在药物开发中确定产品功效和安全性的应用正在扩大。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生物标记市场：依产品/服务分类

  • 消耗品
  • 服务
  • 软体

第七章生物标誌物市场：依类型

  • 功效生物标记
    • 动态标记
    • 预测生物标记
    • 预测生物标记
    • 替代生物标记
  • 安全生物标记
  • 检验生物标记

第八章生物标记市场：依疾病分类

  • 癌症
  • 心血管疾病
  • 免疫疾病
  • 感染疾病
  • 神经系统疾病

第九章生物标记市场：依应用分类

  • 临床诊断
  • 临床调查
  • 药物发现与开发
  • 个人化医疗

第10章美洲生物标记市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生物标记市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的生物标记市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Owlstone Medical 的创新计画获得比尔及梅琳达盖兹基金会的资助
    • 开创性研究合作加强转移性大肠直肠癌的治疗
    • FDA 启动试验计画来监管肿瘤药物的伴同性诊断测试
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Abcam PLC
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix
  • Biocrates Life Sciences AG
  • Biofourmis Inc.
  • Biognosys AG
  • BioStarks
  • Charles River Laboratories, Inc.
  • Elo Health, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Merck KgaA
  • Nightingale Health Plc
  • Owkin Inc.
  • Owlstone Medical Limited
  • PerkinElmer, Inc.
  • Personalis, Inc.
  • Proteomedix AG
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Thermo Fisher Scientific, Inc.
  • VivoSense, Inc
Product Code: MRR-A339DAEFACD9

The Biomarkers Market was valued at USD 52.50 billion in 2023, expected to reach USD 59.69 billion in 2024, and is projected to grow at a CAGR of 14.19%, to USD 132.98 billion by 2030.

Biomarkers, or biological markers, are distinctive biological signatures found in bodily fluids or tissues that indicate normal or abnormal conditions, stage of a disease, or the effects of treatment. They are critical for diagnostics, clinical trials, personalized medicine, and drug development, enhancing understanding of disease mechanisms and treatment efficacy. Biomarkers are used in areas like oncology, cardiology, neurology, and infectious diseases. Market growth is driven by increased prevalence of chronic diseases, technological advancements in biomarker research, and a surge in demand for precision medicine. Innovations in genomic biomarkers, especially through advances in AI and data analytics, present vast opportunities, particularly in tailoring individualized treatment plans and predicting disease progression. Emerging fields like liquid biopsy and multi-omic biomarkers are notable for their potential in earlier and more precise disease detection. Nonetheless, challenges include high costs of validation, regulatory complexities, and ethical issues related to genetic data privacy. Moreover, the heterogeneity of diseases and the lack of standardization in biomarker validation impede expansive market growth. Continued innovation is possible through research into non-invasive biomarkers and AI-enhanced analytical tools. Integration of digital health data and real-world evidence can lead to more predictive diagnostics. Companies can gain competitive advantage by investing in collaborations across industries, ensuring robust interdisciplinary approaches to biomarker discovery. Encouraging open data sharing and standardization protocols can ameliorate some existing barriers. As the biomarker market evolves, an agile approach to regulatory changes and technological advancements will be key for sustained growth. Emphasizing partnerships with healthcare providers and patients will further innovate biomarker applications, leading to significant advancements in health outcomes and market penetration in personalized healthcare solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 52.50 billion
Estimated Year [2024] USD 59.69 billion
Forecast Year [2030] USD 132.98 billion
CAGR (%) 14.19%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biomarkers Market

The Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of biomarkers in early detection and diagnosis of chronic disease
    • Governments and regulatory support for biomarker research
    • Growing applications of biomarkers in personalized medicine
  • Market Restraints
    • High cost and technical issues associated with developing biomarkers
  • Market Opportunities
    • Integration of biomarkers with artificial intelligence and machine learning
    • Growing interest in developing advanced noninvasive biomarkers
  • Market Challenges
    • Ethical and legal concerns regarding the use of biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biomarkers Market

A detailed market share analysis in the Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biomarkers Market

A strategic analysis of the Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product & Service, market is studied across Consumables, Services, and Software.
  • Based on Type, market is studied across Efficacy Biomarkers, Safety Biomarkers, and Validation Biomarkers. The Efficacy Biomarkers is further studied across Pharmacodynamic Biomarkers, Predictive Biomarkers, Prognostic Biomarkers, and Surrogate Biomarkers.
  • Based on Disease, market is studied across Cancer, Cardiovascular Diseases, Immunological Diseases, Infectious Diseases, and Neurological Diseases.
  • Based on Application, market is studied across Clinical Diagnostics, Clinical Research, Drug Discovery & Development, and Personalized Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for biomarker research
      • 5.1.1.3. Growing applications of biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of biomarkers with artificial intelligence and machine learning
      • 5.1.3.2. Growing interest in developing advanced noninvasive biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product & Service: Growing adoption of sophisticated and user-friendly biomarker software to handle the complexity of biological data
    • 5.2.2. Application: Growing applications of biomarkers in drug development to determine the efficacy and safety of the product
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biomarkers Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Biomarkers Market, by Type

  • 7.1. Introduction
  • 7.2. Efficacy Biomarkers
    • 7.2.1. Pharmacodynamic Biomarkers
    • 7.2.2. Predictive Biomarkers
    • 7.2.3. Prognostic Biomarkers
    • 7.2.4. Surrogate Biomarkers
  • 7.3. Safety Biomarkers
  • 7.4. Validation Biomarkers

8. Biomarkers Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Immunological Diseases
  • 8.5. Infectious Diseases
  • 8.6. Neurological Diseases

9. Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Diagnostics
  • 9.3. Clinical Research
  • 9.4. Drug Discovery & Development
  • 9.5. Personalized Medicine

10. Americas Biomarkers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biomarkers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biomarkers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
    • 13.3.2. Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
    • 13.3.3. FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam PLC
  • 3. APIS Assay Technologies Limited
  • 4. Augurex Life Sciences Corp
  • 5. Bio-Rad Laboratories, Inc.
  • 6. BioAgilytix
  • 7. Biocrates Life Sciences AG
  • 8. Biofourmis Inc.
  • 9. Biognosys AG
  • 10. BioStarks
  • 11. Charles River Laboratories, Inc.
  • 12. Elo Health, Inc.
  • 13. F. Hoffmann-La Roche, Ltd.
  • 14. Merck KgaA
  • 15. Nightingale Health Plc
  • 16. Owkin Inc.
  • 17. Owlstone Medical Limited
  • 18. PerkinElmer, Inc.
  • 19. Personalis, Inc.
  • 20. Proteomedix AG
  • 21. QIAGEN GmbH
  • 22. Siemens Healthineers AG
  • 23. Sino Biological Inc.
  • 24. Thermo Fisher Scientific, Inc.
  • 25. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOMARKERS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOMARKERS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOMARKERS MARKET SIZE, BY PHARMACODYNAMIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOMARKERS MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOMARKERS MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOMARKERS MARKET SIZE, BY SURROGATE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOMARKERS MARKET SIZE, BY SAFETY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOMARKERS MARKET SIZE, BY VALIDATION BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOMARKERS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOMARKERS MARKET SIZE, BY IMMUNOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOMARKERS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOMARKERS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY EFFICACY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023